Clinical trial · Observational
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
NCT05746182CI-TRIAL-00101664PanNENrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hereditary Cancer Panel | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with Pancreatic Neuroendocrine Neoplasms
- interventionNames
- Diagnostic Test: Hereditary Cancer Panel
Primary outcomes (1)
- measure
- Rate of overall pathogenic germline mutations
- timeFrame
- Up to 2 years
- description
- The overall percentage of participants with pathogenic, or likely pathogenic germline mutations will be reported with 95% confidence intervals
Secondary outcomes (4)
- measure
- Rates of different types of pathogenic mutations
- timeFrame
- Up to 2 years
- description
- The percentage of participants with each identified type of pathogenic, or likely pathogenic, will be reported with 95% confidence intervals
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed PanNEN. a. The diagnostic biopsy may have been taken from any site (primary or metastatic). 2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years). 3. Participants willing and able to comply with the study procedures. Exclusion Criteria: 1. Inability to provide informed consent. 2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes: 1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic). 2. Active hematologic malignancy. 3. History of allogenic bone marrow transplant or stem cell transplant.
References
Publications (0)
Data not yet available
No reference posted for this study.